Journal article

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy

Danielle Ferraro, John Zalcberg

Therapeutic Advances in Medical Oncology | SAGE PUBLICATIONS LTD | Published : 2014


Funding Acknowledgements

John R. Zalcberg is the principal AGITG investigator of the EORTC 62005 trial of imatinib in metastatic GIST. He has received research support, travel support and honoraria from Bayer and Novartis over the past 3 years. He has provided expert testimony for Bayer.